Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

EntreMed Receives Notice of NASDAQ Compliance

October 15, 2010 By Bio-Medicine.Org

ROCKVILLE, Md., Oct. 15 /PRNewswire/ — EntreMed, Inc. (Nasdaq:

ENMD), a clinical-stage pharmaceutical company developing
therapeutics for the treatment of cancer, today announced that it
has received a letter from the NASDAQ Stock Market indicating that
it has regained compliance with the minimum $35 million Market
Value of Listed Securities (“MVLS”) requirement for continued
listing on the NASDAQ Capital Market as set forth in NASDAQ
Marketplace Rule 5550(b)(2).(Logo:
http://photos.prnewswire.com/prnh/20010620/ENMDLOGO)

(Logo:
http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO)

On August 17, the Company received a Staff Determination Letter
from NASDAQ stating that it was not in compliance with the rule
because its MVLS failed to meet the required $35 million minimum
for the last 30 consecutive business days.  At that time, the
Company was granted 180 calendar days, or until February 14, 2011,
to regain compliance with the rule.  

In order to regain compliance, the Company was required to
maintain a $35 million MVLS for a minimum of 10 consecutive
business days.  In its October 13, 2010 notification, NASDAQ
provided written confirmation that EntreMed has regained compliance
with the rule and that this matter is now closed.

About EntreMedEntreMed, Inc. is a clinical-stage
pharmaceutical company committed to developing ENMD-2076, a
selective angiogenic kinase inhibitor, for the treatment of cancer.
 ENMD-2076 is currently in a multi-center Phase 2 study in
ovarian cancer and in several Phase 1 studies in solid tumors,
multiple myeloma, and leukemia.  Additional information about
EntreMed is available on the Company’s web site at www.entremed.com and in various
filings with the Securities and Exchange Commission.

Forward Looking StatementsThis release contains
forward-looking

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech